Voyager Therapeutics, Inc. advances gene therapies and other genetic medicines for neurological diseases, utilizing its TRACER AAV capsid discovery platform to engineer vectors capable of efficient delivery to the central nervous system. The pipeline includes programs for Alzheimer’s disease, ALS, Parkinson’s disease, Friedreich’s ataxia, and additional central nervous system disorders, several of which are partnered with leading biopharmaceutical companies. The company aims to modify the course of or potentially cure these conditions by addressing underlying genetic mechanisms.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 5.2 | — | -33.4 | — |
| Q3 2025 | 13.4 | — | -27.9 | — |
| Q4 2025 | 15.3 | — | -27.4 | — |
| Q1 2026 | 2.6 | — | -27.9 | — |
| Q2 2026 | 3.2 | -39.1% | -24.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Crexendo, Inc. (CXDO), Satellos Bioscience Inc. (MSLE), Alpha Cognition Inc. Common Stock (ACOG), Black Rock Coffee Bar, Inc. (BRCB), Iron Dome Acquisition I Corp. (IDAC), Toro Corp. (TORO)